Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psyence Biomedical Ltd. (NASDAQ:PBM), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones.
The company has initiated a Phase IIb clinical trial in Australia to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in …